Vera Therapeutics, Inc. - Class A

The momentum for this stock is not very good. Vera Therapeutics, Inc. - Class A is not a good growth stock. Vera Therapeutics, Inc. - Class A is a mediocre stock to choose.

News

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on September 5, 2024, the Compensation Committee granted inducement awards...\n more…

Vera Therapeutics to Participate at September Investor Conferences

Globe Newswire BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...\n more…

Possible Bearish Signals With Vera Therapeutics Insiders Disposing Stock

Simply Wall St Many Vera Therapeutics, Inc. ( NASDAQ:VERA ) insiders ditched their stock over the past year, which may be of interest...\n more…

Vera Therapeutics price target lowered by $3 at JPMorgan, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire BRISBANE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on August 6, 2024, the Compensation Committee granted inducement awards consisting of...\n more…

Vera Therapeutics' Atacicept Secures Buy Rating Amid Strong Financials and Promising Clinical Trials

TipRanks Financial Blog no summary\n more…